Predicting Benefit From FOLFOXIRI Plus Bevacizumab in Patients With Metastatic Colorectal Cancer.
Marinde J G BondMaarten van SmedenKoen DegelingChiara CremoliniHans-Joachim E SchmollCarlotta AntoniottiSara LonardiSabina MurgioniDaniele RossiniStefan IbachMiriam KoopmanRutger-Jan SwijnenburgCornelis J A PuntKatie M O'BrienJohannes J M KwakmanPublished in: JCO clinical cancer informatics (2024)
Although 2-year mortality could be reasonably estimated, the HTE analysis showed that clinically available variables did not reliably identify which patients with mCRC benefit from FOLFOXIRI versus FOLFOX/FOLFIRI, both plus bevacizumab, across the three studies.